December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

142.88 +0.48 (+0.34%)
Official Closing Price Updated: 7:00 PM EDT, Jun 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,511,205
Open 143.07
Bid (Size) 142.91 (1)
Ask (Size) 144.50 (1)
Prev. Close 142.40
Today's Range 142.27 - 143.73
52wk Range 75.56 - 143.73
Shares Outstanding N/A
Dividend Yield 1.24%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Structure Therapeutics' Stock Is Soaring on the Promise of Its Wegovy Competitor, but Is It a Buy?
Structure Therapeutics has a long way to go before beating Wegovy. 
Via The Motley Fool
Here's Why Demand for Ozempic and Wegovy Could Soar Even Higher
Novo Nordisk's stock may not look all that expensive when you're focusing on the long-term potential. 
Via The Motley Fool

Performance

YTD
+39.93%
+39.93%
1 Month
+11.05%
+11.05%
3 Month
+8.87%
+8.87%
6 Month
+47.83%
+47.83%
1 Year
+75.82%
+75.82%

More News

Read More
Profiting from the Crowd: 3 Stocks Set to Surge on Retail Investor Enthusiasm
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Over 10,000 Lawsuits In Novo Nordisk's Ozempic Case Assigned to New Judge
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Novo Nordisk's Options Frenzy: What You Need to Know
Via Benzinga
$100 Invested In Novo Nordisk 10 Years Ago Would Be Worth This Much Today
Via Benzinga
ETFs Bet High On Weight Loss Drugs, But Industry Observers Question Long-Term Potential
Via Benzinga
Topics ETFs
Ozempic, Wegovy Create Domino Effect As New Products Emerge Across Industries To Capture New Consumer Habits
Via Benzinga
The 3 Most Undervalued Pharma Stocks to Buy in June 2024
Via InvestorPlace
Topics Economy
Exposures Economy
Why Quality Investors Should Delve into NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) for Investment Opportunities.
Via Chartmill
Is Viking Therapeutics Stock a Buy on the Dip?
Via The Motley Fool
Ozempic Just Got Even More Bullish For Novo Nordisk Stock, Yet Again
Via The Motley Fool
Chinese Generic Ozempic, Wegovy Versions Could Put Novo Nordisk At The Risk Of Stiff Competition In Key Market
Via Benzinga
Biotech Blockbusters: 3 Pharma Stocks to Buy in June for Breakthrough Potential
Via InvestorPlace
British Agency Supports Eli Lilly's Weight Loss Drug Mounjaro, Diverging From Restrictions on Rival Novo Nordisk's Wegovy
Via Benzinga
Here Are 3 More Reasons to Be Bullish on Ozempic and Novo Nordisk Stock
Via The Motley Fool
Hims & Hers Health Soars on Generic GLP-1 Rollout Plans
Via MarketBeat
The Week Ahead: What's Next
Via Talk Markets
Prediction: These Could Be the Best-Performing Pharmaceutical Stocks Through 2030
Via The Motley Fool
Ozempic and Wegovy Are Fueling Novo Nordisk's Business, but Something Else May Be an Even Bigger Growth Driver in the Long Run
Via The Motley Fool
This Is the Biggest Risk for Eli Lilly and Novo Nordisk Investors
Via The Motley Fool
S&P 500 Giants Lead Five Healthy Stocks Near Buy Points
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Novo Nordisk Is At The Vanguard Of The Weight Drug Revolution
Via Talk Markets
Novo Nordisk Sues Additional US Clinics Against Fake Semaglutide Products Used For Weight Loss, Diabetes
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.